Araliadiol

Araliadiol is a polyacetylenic compound isolated from the leaves of Aralia cordata Thunb. Araliadiol inhibits MCF-7 cells growth with an IC50 value of 6.41 µg/mL[1].

Research Areas >> Cancer

Signaling Pathways >> Others >> Others

IC50: 6.41 µg/mL (MCF-7 cells growth)[1]

Araliadiol (20-80 µM; 0-48 hours; MCF-7 cells) treatment inhibits cell cycle progression of MCF-7 at the G1-S transition[1]. Araliadiol (20-80 µM; 0-48 hours; MCF-7 cells) treatment inhibits phosphorylation of retinoblastoma protein (Rb) in MCF-7 cells, accompanies by a decrease in the levels of cyclin D3 and cdk4 and an increase in the expression of p21 (WAF-1/Cip1)[1]. Cell Cycle Analysis[1] Cell Line: MCF-7 cells Concentration: 20 µM, 40 µM, and 80 µM Incubation Time: 0 hour, 6 hours, 12 hours, 18 hours, 24 hours, and 48 hours Result: The proportion of cells in the G1 phase of the cell cycle increased in a dose-dependent manner (from 54.7 % to 72.0 %). Western Blot Analysis[1] Cell Line: MCF-7 cells Concentration: 20 µM, 40 µM, and 80 µM Incubation Time: 48 hours Result: Phosphorylation of retinoblastoma protein (Rb) in MCF-7 cells was inhibited, accompanied by a decrease in the levels of cyclin D3 and cyclin-dependent kinase 4 (cdk4) and an increase in the expression of p21 (WAF-1/Cip1).

[1]. Cheng WL, et al. Inhibitory effect of human breast cancer cell proliferation via p21-mediated G1 cell cycle arrest by araliadiol isolated from Aralia cordata Thunb. Planta Med. 2011 Jan;77(2):164-8.